Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting

Fig. 4

Multiplex positivity in anti-CCP-2-negative RA patients does not correlate with clinical outcome. a Scheme depicts the number of patients whose UA was diagnosed at baseline. Patients were followed for 1 year to study their progression toward RA. b Median SHS during 7 years of follow-up in anti-CCP-2-negative (n = 1010) and -positive (n = 1330) RA patients. c Median SHS during 7 years of follow-up in anti-CCP-2 negative RA patients who are multiplex-negative (n = 729) or -positive (n = 281). d Median SHS during 7 years of follow-up in multiplex-positive RA patients who are anti-CCP-2-negative (n = 281) or -positive (n = 1282). CCP cyclic citrullinated peptide, CI confidence interval, N number of radiographs, OR odds ratio, RA rheumatoid arthritis, SHS Sharp-van der Heijde score, UA undifferentiated arthritis

Back to article page